If you’ve spent time in patient communities lately, you’ve probably noticed more conversations about newer treatments, especially biologics and other targeted therapies. Many people are asking whether options exist beyond steroids, whether these newer medications might work better, and whether they could eventually offer safer or more personalized approaches for vulvar lichen sclerosus (VLS). These are thoughtful and important questions. As targeted treatments become available for other inflammatory diseases, it is natural for people living with VLS to wonder whether similar advances might apply here. To understand where things stand, it helps to explore what targeted therapies are, how they work, and how they compare to our current standard of care. Disclaimers *This post comes from a review of evidence-based literature on vulvar lichen sclerosus. Importantly, it is Jaclyn’s interpretation of the literature and its findings. It is up to date as of February 2026. **If this post is helpful…